Chemotherapy Drives Tertiary Lymphoid Structures That Correlate with ICI-Responsive TCF1+CD8+ T Cells in Metastatic Ovarian Cancer
2024

Chemotherapy Enhances Immune Response in Ovarian Cancer

Sample size: 130 publication 10 minutes Evidence: high

Author Information

Author(s): Tereza Lanickova, Michal Hensler, Lenka Kasikova, Sarka Vosahlikova, Artemis Angelidou, Josef Pasulka, Hannah Griebler, Jana Drozenova, Katerina Mojzisova, Ann Vankerckhoven, Jan Laco, Ales Ryska, Pavel Dundr, Roman Kocian, David Cibula, Tomas Brtnicky, Petr Skapa, Francis Jacob, Marek Kovar, Ivan Praznovec, Iain A. McNeish, Michal J. Halaska, Lukas Rob, An Coosemans, Sandra Orsulic, Lorenzo Galluzzi, Radek Spisek, Jitka Fucikova

Primary Institution: Sotio Biotech, Prague, Czech Republic

Hypothesis

Can neoadjuvant chemotherapy improve the immune response in high-grade serous ovarian carcinoma (HGSOC) patients?

Conclusion

Neoadjuvant chemotherapy promotes the formation of immune structures and enhances the presence of immune cells that are sensitive to immunotherapy in metastatic ovarian cancer.

Supporting Evidence

  • NACT increases the density of immune cells in metastatic HGSOC.
  • Chemotherapy enhances the formation of tertiary lymphoid structures.
  • Patients receiving NACT showed improved overall survival.
  • TCF1+PD1+CD8+ T cells were more prevalent in NACT-treated patients.
  • Chemotherapy combined with PD1-targeting ICI showed significant survival benefits in mouse models.
  • NACT promotes an ICI-sensitive immune environment in metastatic HGSOC.

Takeaway

Chemotherapy can help the body's immune system fight ovarian cancer better by making it easier for immune cells to attack the cancer.

Methodology

The study analyzed paired primary and metastatic tumor samples from patients using transcriptomic, spatial, and functional assays.

Potential Biases

Potential biases in patient selection and retrospective data collection.

Limitations

The study is retrospective and may not account for all variables affecting immune response.

Participant Demographics

Patients with high-grade serous ovarian carcinoma, FIGO stage III + IV.

Statistical Information

P-Value

p<0.05

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1158/1078-0432.CCR-24-1594

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication